Current Challenges of Gene Therapy for Prostate Cancer

ONCOLOGY

Volumn 11, Issue 6, 1997, Pages 845-856

  Harrison, Gail S ^a   Glode, L Michael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; DRUG DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; REVIEW; SAFETY; TREATMENT OUTCOME; VIRUS;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; PROSTATIC NEOPLASMS; SAFETY; TREATMENT OUTCOME; VIRUSES;

EID: 0031158978     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics. 1996. CA Cancer J Clin 46:5-27, 1996.
2. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: What we know and what we need to know [see comments]. Ann Intern Med 119:914-923, 1993.
3. Fleming C, Wasson JH, Albertsen PC, et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer: Prostate Patient Outcomes Research Team [see comments]. JAMA 269:2650-2658, 1993.
4. Hanks GE: External beam radiation treatment for prostate cancer Still the gold standard [see comments]. Oncology 6:79-86, 89; 90-94 [discussion], 1992.
5. Cher ML, Shinohara K, Brelin S, et al: High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol 75:771-777, 1995.
6. Soloway MS, Sharifi R, Wajsman Z, et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer: The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154:424-428, 1995.
7. Fair WR, Aprikian AG, Cohen D, et al: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 16:516-522, 1993.
8. Isreali RS, Wang Y, Fair WR, et al: Neoadjuvant androgen-deprivation therapy (ADT) prior to radical prostatectomy results in a significant decrease in residual micrometastases as detected by nested RT-PCR with PSM primers (abstract). Proc Ann Meet Am Assoc Cancer Res 36: A3823, 1995
9. Witjes WP, Oosterhof GO, Schaafsma HE, et al: Current status of neoadjuvant therapy in localized prostate cancer. Prostate 27:297-303, 1995.
10. Anderson WF: Gene therapy Sci Am 273:124-128, 1995.
11. Marshall E: Gene therapy's growing pains. Science 269:1050-1055, 1995
12. Ross G, Erickson R, Knorr D, et al: Gene therapy in the United States: A five-year status report. Human Gene Ther 7:1781-1790, 1996.
13. Blaese M, Blankenstein T, Brenner M, et al: Vectors in cancer therapy How will they deliver? Cancer Gene Ther 2:291-297, 1995.
14. Dunbar CE, Cottler-Fox M, O' Shaughnessy JA, et al: Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85:3048-3057, 1995.
15. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383, 1994.
16. Parkman R, Barrantes B, Weinberg KI, et al: Analysis of T lymphocytes from patients with adenosine deaminase (ADA) deficiency transplanted with ADA transduced cord blood cells (abstract). J Cell Biochem 21 A(suppl):369, 1995.
17. Mullen CA, Snitzer K, Culver KW, et al: Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: Long-term expression in vivo of genes introduced with a retroviral vector. Human Gene Ther 7:1123-1129, 1996.
18. Kohn DB, Weinberg KI, Nolta JA, et al: Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Medicine 1:1017-1023, 1995.
19. Crystal RG, McElvaney NG, Rosenfeld MA, et al: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet 8:42-51, 1994.
20. MeKeon C, Samulski RJ: NIDDK workshop on AAV vectors: Gene transfer into quiescent cells. Human Gene Ther 1:1615-1619, 1996.
21. Nabel GJ, Chang AE, Nabel EG, et al: Immunotherapy for cancer by direct gene transfer into tumors Human Gene Ther 5:57-77, 1994.
22. Hersh EM, Akporiaye E, Harris D, et al: Phase I study of immunotherapy of malignant melanoma by direct gene transfer. Human Gene Ther 5:1371-1384, 1994.
23. Donahue RE, Kessler SW, Bodine D, et al: Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 176-1125-1135, 1992
24. Dhom G: Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 106:210-218, 1983.
25. Breslow B, Chan CW, Dhom G, et al: Latent carcinoma of prostate at autopsy in seven areas: Collaborative study organized by the international agency for research on cancer, Lyons, France. Int J Cancer 20:680-688, 1977.
26. Holund B: Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 14:29, 1980.
27. Breitman ML, Clapoff S, Rossant J, et al: Genetic ablation: Targeted expression of a toxin gene causes microphthalmia in transgenic mice. Science 238:1563-1565, 1987.
28. Zhang WW, Roth JA. Anti-oncogene and tumor suppressor gene therapy - examples from a lung cancer animal model. In Vivo 8:755-769, 1994.
29. Berube NG, Speevak MD, Chevrette M: Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del(12)(q13). Cancer Res 54:3077-3081, 1994.
30. Kleinerman DI, Zhang WW, Lin SH, et al: Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: A preclinical study. Cancer Res 55:2831-2836, 1995.
31. Ware JL: Growth factors and their receptors as determinants in the proliferation and me tastasis of human prostate cancer. Cancer Met Rev 12:287-301, 1993
32. Fielder PJ, Rosenfeld RG, Graves HC, et al: Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regulation 4:164-172, 1994.
33. Trinh QT, Austin EA, Murray DM, et al: Enzyme/prodrug gene therapy Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55:4808-4812, 1995.
34. Freeman SM, Abboud CN, Whartenby KA, et al: The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 53:5274-5283, 1993.
35. Vieweg J, Gilboa E Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Invest 13:193-201, 1995.